For those that haven’t go and take a gander at the LinkedIn profile of the new appointee, and look at his experience and names of the big pharma that he has worked for.
”Bench to Bedside” experience taking compounds and molecules to market.
We can all speculate until the cows come home about Fuller, but given the farewell team photo Dr. T just posted on twitter I think you can put aside anything other than an amicable departure.
For those that haven’t go and take a gander at the LinkedIn...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.68 |
Change
0.050(3.08%) |
Mkt cap ! $285.4M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.75 | $1.64 | $210.4K | 125.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5000 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 595 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |